Article Versions Notes

Fahrmann JF, Tanaka I, Irajizad E, Mao X, Dennison JB, Murage E, Casabar J, Mayo J, Peng Q, Celiktas M, et al. Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma. Cancers. 2022; 14(10):2543. https://doi.org/10.3390/cancers14102543

Fahrmann, Johannes F., Ichidai Tanaka, Ehsan Irajizad, Xiangying Mao, Jennifer B. Dennison, Eunice Murage, Julian Casabar, Jeffrey Mayo, Qian Peng, Muge Celiktas, and et al. 2022. "Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma" Cancers 14, no. 10: 2543. https://doi.org/10.3390/cancers14102543

Fahrmann, J. F., Tanaka, I., Irajizad, E., Mao, X., Dennison, J. B., Murage, E., Casabar, J., Mayo, J., Peng, Q., Celiktas, M., Vykoukal, J. V., Park, S., Taguchi, A., Delgado, O., Tripathi, S. C., Katayama, H., Soto, L. M. S., Rodriguez-Canales, J., Behrens, C., ... Ostrin, E. J. (2022). Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma. Cancers, 14(10), 2543. https://doi.org/10.3390/cancers14102543